What does this research mean for the field?

In real-world clinical practice, both upadacitinib and abrocitinib are effective and generally safe for managing moderate-to-severe atopic dermatitis over 24 weeks, with comparable overall efficacy despite a numerically higher EASI-50 response for upadacitinib. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This study aims to compare the effectiveness and safety of upadacitinib versus abrocitinib in patients with moderate-to-severe atopic dermatitis over 24 weeks.

May 29, 2026PharmaceuticalsOpen Access

Real-World Effectiveness and Safety of Upadacitinib Versus Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A Retrospective Cohort Study

View Full Paper

Ask AI

Bookmark

Authors

ÖKÖmer KarakoyunDicle University EAErhan AyhanDicle University

Discussion

Member takes

Implication

Retrospective cohort study comparing treatment outcomes in adults with moderate-to-severe dermatitis, indicating potential considerations for therapy selection.

Key Points

This study aims to compare the effectiveness and safety of upadacitinib versus abrocitinib in patients with moderate-to-severe atopic dermatitis over 24 weeks.
Retrospective single-center study of adults treated with either upadacitinib 30 mg or abrocitinib 200 mg.
Follow-up period of 24 weeks, assessing clinical outcomes using EASI and safety via reported adverse events.
Exploratory analysis of factors such as BMI, IgE levels, and psychological stress on treatment responses.
EASI-75 response at month 6 was 83.3% for upadacitinib and 70.8% for abrocitinib (p = 0.27).
EASI-50 response was significantly higher for upadacitinib at 100% versus 83.3% for abrocitinib (p = 0.05).
Both medications demonstrated favorable safety profiles, with one serious adverse event noted in a patient with pre-existing risks.

Cite This Study

Karakoyun et al. (2026) studied this question.

synapsesocial.com/papers/6a192ea9fab5b468c4417cc5 https://doi.org/10.3390/ph19060828

View Full Paper

Ask AI

Bookmark

May 29, 2026PharmaceuticalsOpen Access

Real-World Effectiveness and Safety of Upadacitinib Versus Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A Retrospective Cohort Study

View Full Paper

Ask AI

Bookmark

Authors

ÖKÖmer KarakoyunDicle University EAErhan AyhanDicle University

Discussion

Member takes

Implication

Retrospective cohort study comparing treatment outcomes in adults with moderate-to-severe dermatitis, indicating potential considerations for therapy selection.

Key Points

This study aims to compare the effectiveness and safety of upadacitinib versus abrocitinib in patients with moderate-to-severe atopic dermatitis over 24 weeks.
Retrospective single-center study of adults treated with either upadacitinib 30 mg or abrocitinib 200 mg.
Follow-up period of 24 weeks, assessing clinical outcomes using EASI and safety via reported adverse events.
Exploratory analysis of factors such as BMI, IgE levels, and psychological stress on treatment responses.
EASI-75 response at month 6 was 83.3% for upadacitinib and 70.8% for abrocitinib (p = 0.27).
EASI-50 response was significantly higher for upadacitinib at 100% versus 83.3% for abrocitinib (p = 0.05).
Both medications demonstrated favorable safety profiles, with one serious adverse event noted in a patient with pre-existing risks.

Cite This Study

Karakoyun et al. (2026) studied this question.

synapsesocial.com/papers/6a192ea9fab5b468c4417cc5 https://doi.org/10.3390/ph19060828

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark